LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LGP

LGP - LITTLE GREEN PHARMA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.55
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.099

30 Jun
2025

-0.001

OPEN

$0.10

-1.00%

HIGH

$0.11

435,678

LOW

$0.10

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202022202320242025
EPS Basic xxxxxxxxxxxxxxx1.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx36.8 M
Book Value Per Share xxxxxxxxxxxxxxx28.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-0.9 M
Net Profit Margin xxxxxxxxxxxxxxx9.03 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx4.10 %
Return on Invested Capital xxxxxxxxxxxxxxx3.98 %
Return on Assets xxxxxxxxxxxxxxx3.64 %
Return on Equity xxxxxxxxxxxxxxx4.10 %
Return on Total Capital xxxxxxxxxxxxxxx-4.71 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx1 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2 M
Price To Book Value xxxxxxxxxxxxxxx0.45

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202022202320242025
Capex xxxxxxxxxxxxxxx0.7 M
Capex % of Sales xxxxxxxxxxxxxxx1.97 %
Cost of Goods Sold xxxxxxxxxxxxxxx29 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx12 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

07/05/2025

1

Speculative Buy

$0.18

81.82%

Canaccord Genuity lowers its price target for Little Green Pharma to $0.18 from $0.21 while retaining a Speculative Buy rating.

The analyst explains March quarter result met expectations, though gross profit margins declined for a third consecutive quarter to 33%, leading to trimmed earnings (EBITDA) forecasts to $0.6m from $0.9m, and FY26 to $3.9m from $4.5m.

The broker's net income estimated for FY26 is reduced to $0.8m from $1.5m.

Revenue forecast for FY25 is maintained at $36.6m, up 40% year-on-year, with March revenue at a stronger-than-expected $4.0m, indicating a favourable run rate for FY26.

The broker flags the need for careful working capital management given a cash balance of $2.4m. European growth remains a key driver, with March quarter sales in that region rising 50%. 

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.90 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.
Access Extra Coverage Research History >

LGP STOCK CHART

FNArena News on LGP

1
Australian Broker Call *Extra* Edition – May 08, 2025

May 08 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Apr 07, 2025

Apr 07 2025 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 25-10-24

Oct 25 2024 - Weekly Reports
4
In Brief: Aurum, Hillgrove & Little Green Pharma

Oct 25 2024 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Oct 24, 2024

Oct 24 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps